A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma

Trial Profile

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Breast cancer; Lung cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Jun 2017 Results (n=11) assessing safety and activity of erdafitinib in patients with molecularly selected advanced cholangiocarcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2017 Planned End Date changed from 1 Apr 2017 to 29 Dec 2017.
    • 19 May 2017 Planned primary completion date changed from 1 Apr 2017 to 29 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top